Organovo Holdings (ONVO), an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications.
ONVO develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
ONVO offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch.
Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
November 13, 2013
Record lows; paint a picture of what – costs of operating?
November 13, 2013
The Early Movers
November 12, 2013
When the water drops, the surface tension also flattens
November 12, 2013
Like an elephant getting in or out of a bathtub
November 12, 2013
The Early Movers
November 8, 2013
RegMed climbs on Friday but, are retail investors churned out?
November 8, 2013
The bar of attainment gets lower
November 8, 2013
The Early Movers
November 7, 2013
No place to hide; having given up so much already
November 7, 2013
Something’s gotta give; sector needs an ‘itter attachment
35 companies, 1 interpreter!
Insight, foresight and recommendation
Organovo Holdings (ONVO) – ONVO opened on 1/2/18 at $1.39, floating to $1.45 by 2/1 and slipping to $1.05 by 2/12. A show me stock ... the FDA recently granting orphan designation for our NovoTissues® treatment of Alpha-1 antitrypsin deficiency (“A1AT”), our path to commercializing this therapeutic comes with significant developmental and economic incentives. With few alternative therapies and a high annual cost of care, patient need is great in treating this rare, debilitating liver disease. ONVO has also begun new studies in a second therapeutic indication within the category of inborn errors of metabolism, Fumarylacetoacetate Hydrolase (“FAH”) deficiency, and look forward to reporting proof-of-principle data in Q2-3/18. A show me stock ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.